Sanggenol A is primarily studied for its potential anti-cancer properties, particularly in inhibiting the growth of certain tumor cells. It has shown activity against liver, breast, and colon cancer cell lines by inducing apoptosis and suppressing cell proliferation. Additionally, Sanggenol A exhibits anti-inflammatory effects by modulating key signaling pathways such as NF-κB, making it a candidate for research in chronic inflammatory diseases. Its antioxidant activity also supports potential use in reducing oxidative stress-related damage, which is linked to aging and neurodegenerative conditions. Most applications remain in the preclinical research stage, focusing on drug development and natural product-based therapies.